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Synthesis of Aib-containing cyclopeptides via the
'azirine/oxazolone method'
Abstract
The cyclic pentapeptide cyclo[Gly-Phe(2Me)-Aib-Aib-Gly], containing three α,α-disubstituted α-amino
acids, was prepared by cyclization of H-Gly-Phe(2Me)-Aib-Aib-Gly-OH with diphenylphosporazidate
(DPPA) in 60% yield. The synthesis of the linear precursor was performed by using the
‘azirine/oxazolone method', in which the α,α-disubstituted α-amino acids were introduced by coupling
of the corresponding amino or peptide acid with a 2,2-disubstituted 3-amino-2H-azirine. Whereas the
cyclization of an analogous hexapeptide afforded the cyclopeptide in 42% yield, the corresponding
tetrapeptide yielded a 1:2 mixture of the monomeric and dimeric cyclopeptide. In the case of the
tripeptide H-Gly-Phe(2Me)-Aib-OH, the cyclization with DPPA led to the dimeric cyclohexapeptide
exclusively.
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The cyclic pentapeptide cyclo[Gly-Phe(2Me)-Aib-Aib-Gly], containing three α,α-disubstituted
α-amino acids, was prepared by cyclization of H-Gly-Phe(2Me)-Aib-Aib-Gly-OH with diphenyl
phosporazidate (DPPA) in 60% yield. The synthesis of the linear precursor was performed by
using the ‘azirine/oxazolone method’, in which the α,α-disubstituted α-amino acids were in-
troduced by coupling of the corresponding amino or peptide acid with a 2,2-disubstituted
3-amino-2H-azirine. Whereas the cyclization of an analogous hexapeptide afforded the
cyclopeptide in 42% yield, the corresponding tetrapeptide yielded a 1:2 mixture of the
monomeric and dimeric cyclopeptide. In the case of the tripeptide H-Gly-Phe(2Me)-Aib-OH,
the cyclization with DPPA led to the dimeric cyclohexapeptide exclusively.
Keywords: α-Amino acids; 3-Amino-2H-azirines; Peptides; α,α-Disubstituted amino acids;
Cyclizations; X-ray diffraction.
Cyclic peptides are of continuing interest, mainly because of their diverse
biological activities1–8. This is documented by a large series of recent papers
describing the isolation and activity of new naturally occurring cyclo-
peptides9–14. On the other hand, the development of efficient methods for
the synthesis of natural and designed cyclic peptides is a challenging
task15–20, and an increasing number of papers dealing with syntheses of cy-
clic peptides are published year after year21–29. It has been shown that the
yield of the cyclization is not only dependent on the ring size of the prod-
uct but also on the sequence of the amino acids as well as on the position
of the ring closure (e.g. refs.30,31). One of the main problems in the case of
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the cyclization of tri-, tetra-, and pentapeptides is the formation of dimeric
cyclopeptides30. For example, Kondo et al.32 showed that the cyclization of
H-Val-Orn(Z)-Leu-D-Phe-Pro-ONp led to a ca. 2:1 mixture of gramicidine S
and the monomeric cyclopentapeptide, whereas the corresponding penta-
peptides with Val substituted by Gly or Aib (α-aminoisobutyric acid)
yielded the cyclopentapeptide exclusively. Similarly, Hlaváček et al.33 ob-
tained a 1:1 mixture of the cyclopenta- and the dimeric cyclodecapeptide
when H-Tyr(t-Bu)-Asp(Ot-Bu)-Pro-Ala-Pro-OH was cyclized.
With the ‘azirine/oxazolone method’ we have elaborated a convenient
and efficient access to peptides containing α,α-disubstituted α-amino
acids34 (Scheme 1).
The coupling of an amino acid or a peptide acid 1 with a 3-amino-
2H-azirine 2 yields a peptide amide 3, which is then hydrolyzed selectively
to give the peptide 4. The latter can be coupled with another 2H-azirine 2
or with a C-protected amino acid or peptide. It has been shown that a 1,3-
oxazol-5(4H)-one 5 is formed as an intermediate, which reacts with the
amino component to give the new peptide 6. The smooth ring closure to 5
has been explained as the result of the Thorpe–Ingold effect35. Using this
methodology, we have prepared sterically congested model peptides36–40
and peptaibols41–43, i.e., natural Aib-containing peptide alcohols with anti-
biotic activity44. A characteristic feature of all these peptides is their re-
stricted flexibility and preferred helical structure. Recently we have adopted
the ‘azirine/oxazolone method’ to solid-phase peptide synthesis45.
As an extension of the ‘azirine/oxazolone method’, we have synthesized
cyclic depsipeptides containing α,α-disubstituted α-amino acids via the
Collect. Czech. Chem. Commun. 2009, Vol. 74, No. 6, pp. 901–925
902 Dannecker-Dörig, Linden, Heimgartner:
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so-called ‘direct amide cyclization’34,46–50 (Scheme 2). In these reactions, a
suspension of a peptide containing Aib (R2 = R3 = Me) at the C-terminus of
type 7 (X = O) with a terminal hydroxy group in toluene at 80–100 °C was
treated with gaseous HCl leading to cyclodepsipeptides 9 via formation of
the lactone bond. It has been shown that 1,3-oxazol-5(4H)-ones are inter-
mediates. Therefore, in the case of an optically active penultimate α-amino
acid (R1 ≠ H), partial epimerization has been observed under the conditions
of the ‘direct amide cyclization’. An analogous ring closure giving cyclo-
peptides 11 was achieved via sequential deprotection of 7 (X = NZ or
NFmoc (for abbreviations, see Experimental)) and treatment with a cou-
pling reagent31,51,52. A systematic study revealed that 18-membered cyclo-
hexapeptides are formed in good to excellent yields31,52a,52b, and also
cyclohepta- and cyclooctapeptides (21- and 24-membered rings, respec-
tively) could be obtained in reasonable to good yields52c.
In the present study, the cyclization of tri-, tetra-, penta-, and hexa-
peptides with 2-methylphenylalanine (Phe(2Me)) and Aib in their back-
bone was investigated. Linear precursors with Gly at both termini were
chosen with the aim of avoiding steric hindrance in the cyclization as well
as the formation of an intermediate oxazolone.
RESULTS AND DISCUSSION
Synthesis of Linear Peptides Containing α,α-Disubstituted α-Amino Acids
Following the protocol of the ‘azirine/oxazolone method’, the peptides 15,
17, and 19, containing two, three, and four α,α-disubstituted α-amino ac-
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ids, were prepared (Scheme 3). For example, Z-protected glycine reacted
with racemic 2-benzyl-3-(dimethylamino)-2-phenyl-2H-azirine (2a) in THF
at 0 °C to give dipeptide amide 12 (97%), which was hydrolyzed with 6 M
HCl/THF (1:1) at 35 °C leading to 13 in 92% yield. Repeating the ‘azirine
coupling’ with 2b gave tripeptide amide 14 (84%) and subsequent hydro-
lysis yielded 15 (96%). This coupling/hydrolysis sequence was repeated ac-
cording to Scheme 3.
Synthesis of the Cyclopentapeptide cyclo[Gly-Phe(2Me)-Aib2-Gly]
The first cyclization experiments were carried out with the pentapeptide
H-Gly-Phe(2Me)-Aib-Aib-Gly-OH (21), which was obtained from 17 via
DCC coupling with methyl glycinate, alkaline hydrolysis and hydrogeno-
lytic deprotection of the N-terminus (Scheme 4). The structure of 21 was
deduced from analytical and spectroscopic data and, finally, established by
X-ray crystallography (Fig. 1a, Tables I and II). In the crystal structure of 21,
the asymmetric unit contains one peptide molecule and four molecules of
water. Some of the water H atoms could not be located. The peptide mole-
cule is protonated at the terminal amino group. The molecule is presum-
ably a zwitterion with the terminal carboxylate function; a H atom could
not be located here, but this terminal group has disordered O atoms, which
might inhibit the detection of the hydroxy H atom, even if present. If the
group was protonated, then one of the water molecules would have to be a
hydroxy anion, which seems unlikely. Each N–H group of the molecule acts
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as a donor for hydrogen bonds. Two intramolecular hydrogen bonds
(N(4)–H of Aib(4) with O(1) of Gly(1) and N(5)–H of Gly(5) with O(2) of
Phe(2Me)) form β-turns of type III′ and, therefore, keep the molecule in an
incipient 310-helical conformation (for peptide conformations, see ref.
54).
Each of these interactions has a graph set motif55 of S(10). The ammonium
group forms intermolecular hydrogen bonds with an amide O atom and a
carboxylate O atom of the same neighboring molecule, as well as with the
other carboxylate O atom of a different neighboring molecule. These inter-
actions link the peptide molecules into extended chains which run parallel
to the [010] and [101] directions, respectively, and can be described by
graph set motifs of C(11) and C(17). N(2)–H and N(3)–H form inter-
molecular hydrogen bonds with different water molecules, while the water
molecules form hydrogen bonds between themselves and with amide O
atoms of various neighboring peptide molecules. Where a water H atom
could not be located, the interaction is inferred from suitable O···O dis-
tances. The combination of all intermolecular interactions forms a three-
dimensional network.
The ring closure was achieved under different conditions by using various
peptide-coupling reagents, e.g., with BOP and DMAP in methanol56, with
pentafluorophenol in DMF/CH2Cl2 at room temperature56,57, or with DPPA
in DMF 58,59. In all cases, the solution of the coupling reagent was added
very slowly by using a syringe. The highest yield of the crude cyclopenta-
peptide 22 (85%) was obtained with DPPA. After HPLC purification, 60% of
pure 22 were isolated. The structure of this product was also determined by
X-ray crystallography (Fig. 1b, Tables I and II).
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The asymmetric unit of 22 contains one peptide molecule and one mole-
cule of water. Each N–H group of the peptide molecule and the water mole-
cule act as donors for hydrogen bonds. The molecule contains an intra-
molecular hydrogen bond across the macrocycle (N(4)–H···O(2)), which
forms a β-turn of type I′ and a second one from N(1)–H to O(2), forming
a five-membered loop (C5-conformation, see ref.60), which is unusual for
an Aib residue61. It has to be emphasized that O(2) is a double acceptor of
Collect. Czech. Chem. Commun. 2009, Vol. 74, No. 6, pp. 901–925
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FIG. 1
ORTEP plots53 of the molecular structure of compounds a 21 and b 22 (arbitrary numbering of
atoms; 30 and 50% probability ellipsoids, respectively)
a
b
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TABLE I
Torsion angles of the backbone of compounds 21 and 22 (atom numbering refers to Fig. 1)
Compound Amino acid Atoms Torsion angle, °
21 Gly(1) ω1 C(1)–C(2)–N(2)–C(3) –170.6(2)
Phe(2Me)(2) φ2 C(2)–N(2)–C(3)–C(4) 51.2(3)
ψ2 N(2)–C(3)–C(4)–N(3) 32.5(3)
ω2 C(3)–C(4)–N(3)–C(5) 177.9(2)
Aib(3) φ3 C(4)–N(3)–C(5)–C(6) 50.1(3)
ψ3 N(3)–C(5)–C(6)–N(4) 37.7(3)
ω3 C(5)–C(6)–N(4)–C(7) 174.3(2)
Aib(4) φ4 C(6)–N(4)–C(7)–C(8) 63.2(3)
ψ4 N(4)–C(7)–C(8)–N(5) 28.0(3)
ω4 C(7)–C(8)–N(5)–C(9) 165.1(2)
22 Gly(1) φ1 C(8)–N(4)–C(9)–C(10) –120.9(3)
ψ1 N(4)–C(9)–C(10)–N(5) –122.2(3)
ω1 C(9)–C(10)–N(5)–C(1) 175.8(2)
Phe(2Me)(2) φ2 C(10)–N(5)–C(1)–C(2) –57.7(4)
ψ2 N(5)–C(1)–C(2)–N(1) –25.3(3)
ω2 C(1)–C(2)–N(1)–C(3) 165.2(3)
Aib(3) φ3 C(2)–N(1)–C(3)–C(4) –159.7(3)
ψ3 N(1)–C(3)–C(4)–N(2) 166.4(2)
ω3 C(3)–C(4)–N(2)–C(5) 172.1(2)
Aib(4) φ4 C(4)–N(2)–C(5)–C(6) 56.1(4)
ψ4 N(2)–C(5)–C(6)–N(3) 39.9(4)
ω4 C(5)–C(6)–N(3)–C(7) 177.3(3)
Gly(5) φ5 C(6)–N(3)–C(7)–C(8) 100.0(4)
ψ5 N(3)–C(7)–C(8)–N(4) –16.1(4)
ω5 C(7)–C(8)–N(4)–C(9) 170.8(3)
hydrogen bonds. The pattern of the intramolecular hydrogen bonds in 22
is surprising because it does not correspond with the usually observed con-
formations found for different cyclopentapeptides62,63. These interactions
can be described by graph set motifs55 of S(10) and S(5), respectively. N(3)–H
forms an intermolecular hydrogen bond with the water O atom. N(2)–H
forms an intermolecular hydrogen bond with the same amide O atom of a
neighboring molecule that accepts the N(4)–H intramolecular interaction.
This interaction links the molecules into extended chains which run paral-
lel to the [0 –1 1] direction and which can be described by a graph set motif
of C(8). N(5)–H forms an intermolecular hydrogen bond with another
amide O atom in a different neighboring molecule and thereby links the
molecules into extended chains which run parallel to the [001] direction
and which can be described by a graph set motif of C(5). The water mole-
cule donates hydrogen bonds to amide O atoms in two different peptide
molecules. One of these is back to the same peptide molecule from which
the water molecule accepts a hydrogen bond, which generates a ring with a
graph set motif of R2
2 (10). The other is with a different peptide molecule
and thereby links water and peptide molecules alternately into extended
chains which run parallel to the [011] direction and which can be described
by a binary graph set motif of C 2
2 (6). The combination of all intermolecular
interactions forms a three-dimensional network.
Synthesis of Cyclohexapeptide cyclo[Gly-Phe(2Me)-Aib3-Gly]
The cyclohexapeptide 25 was prepared in an analogous manner to the
above described synthesis of cyclopentapeptide 22 (Scheme 5). The cou-
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Intramolecular hydrogen bonds of compounds 21, 22, and 31a (atom numbering refers to
Figs. 1 and 2)
Compound Hydrogen bond N–H, Å H···O, Å N···O, Å N–H···O, °
21 N(4)–H···O(1) 0.81(2) 2.30(2) 3.050(3) 155(2)
N(5)–H···O(2) 0.86(3) 2.12(3) 2.960(3) 167(2)
22 N(1)–H···O(2) 0.84(3) 2.05(3) 2.538(3) 117(3)
N(4)–H···O(2) 0.87(3) 2.20(3) 3.028(3) 160(2)
31a N(10)–H···O(1) 0.88 2.05 2.895(8) 161
N(22)–H···O(5) 0.88 2.24 2.999(9) 145
pling of the pentapeptide 19 and benzyl glycinate in DMF with DCC in the
presence of ZnCl2, followed by hydrogenolytic deprotection, gave
hexapeptide 24 in 83% yield. Cyclization of the latter with DPPA yielded,
after HPLC purification, the cyclohexapeptide 25 (42%). The structure was
supported by the 1H and 13C NMR spectra and the comparison of the data
with those of 22 and by FAB-MS. Based on this experiment, a series of addi-
tional cyclohexapeptides with analogous structures have been prepared and
their 3D-structure established by X-ray crystallography31,52a,52b.
Attempted Synthesis of Cyclotripeptide cyclo[Gly-Phe(2Me)-Aib] and
Cyclotetrapeptide cyclo[Gly-Phe(2Me)-Aib-Gly]
Encouraged by the successful preparation of Phe(2Me) and Aib containing
cyclopenta- and cyclohexapeptides, the more demanding synthesis of a
strained cyclotripeptide, as well as a cyclotetrapeptide, was undertaken. As
a tripeptide, H-Gly-Phe(2Me)-Aib-OH (26) was chosen, which was obtained
by the hydrogenolytic deprotection of the terminal amino group of 15. The
cyclization with DPPA led, after purification by HPLC, to a product, which
most likely is a mixture of diastereoisomeric cyclodimers, i.e., cyclohexa-
peptide 27 (Scheme 6). No decision concerning the relative configuration
of the two Phe(2Me) units was possible on the basis of the NMR data, but
the 13C NMR spectrum and the 1H NMR spectra at different temperatures
indicate the presence of two diastereoisomers. All attempts to favor the for-
mation of the monomeric cyclotripeptide by carring out the cyclization in
more dilute solutions were in vain. The failure of the cyclization to the
nine-membered cyclotripeptide can be explained kinetically by the in-
creased steric hindrance in the case of a C-terminal Aib and thermodynami-
cally by the high ring strain of nine-membered rings.
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The coupling of Z-protected tripeptide 15 and H-Gly-OBn with DCC/ZnCl2
in DMF 34,64 gave the protected tetrapeptide 28 in 95% yield (Scheme 6).
Simultaneous deprotection of both the amino and carboxyl group was
achieved by hydrogenolysis, leading to 29 (85%). Treatment of the latter
with DPPA under the usual conditions gave a complex mixture of products.
Their separation by HPLC led to two fractions, which, according to FAB-MS,
were still mixtures of cyclotetrapeptide 30, cyclodimer and cyclotrimer.
With the aim of reducing the oligomerization, the cyclization was re-
peated in higher dilution (0.19 mmol of 29 in 200 ml of DMF instead of
0.21 mmol in 23 ml of DMF). After the usual workup, reversed-phase HPLC
gave two fractions in a ratio of 1:2 (ca. 45% total yield). The first fraction
contained a single product, which, according to the FAB-MS was the cyclo-
tetrapeptide 30 (Scheme 6). The second fraction consisted of two diastereo-
isomeric cyclodimers 31a and 31b, which could be separated by another
HPLC and were isolated as crystalline materials. The structures of these
products were proposed on the basis of their FAB-MS and 1H and 13C NMR
data, but it was not possible to assign the relative configurations of the two
Phe(2Me) residues. Fortunately, one of the two isomers, 31a, after crystalli-
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zation from methanol, was obtained as single crystals suitable for an X-ray
crystal-structure determination, which established the presence of the cis-
isomer, that is the (R,R/S,S) diastereoisomer (Fig. 2, Tables II and III). The
conformation of the 24-membered ring is stabilized by two intramolecular
hydrogen bonds (N(10)–H···O(1) and N(22)–H···O(5)), which form two β-turns
of type III′ including Phe(2Me) and Aib.
Since the space group of 31a is centrosymmetric, the compound in the
crystal is racemic. The asymmetric unit contains one molecule of the pep-
tide plus five molecules of MeOH, one of which is disordered. As expected,
the peptide is a cyclic dimeric molecule, which almost possesses pseudo
two-fold symmetry, although the N(1)/O(8) and N(13)/O(4) regions deviate
significantly from a two-fold relationship. The crystals were very weakly
diffracting and gave limited observed intensities, probably partially due to a
large amount of solvent in the crystal lattice. The crystals lost solvent and
were destroyed immediately upon removal from the mother liquor; there-
fore it was necessary to mount a crystal in a capillary together with some
mother liquor without the crystal ever leaving the solution. Each N–H
group of the molecule acts as a donor for hydrogen bonds. Every second
amide N–H group [N(1)–H, N(7)–H, N(13)–H, N(19)–H] forms an inter-
molecular hydrogen bond with the O atom of a different MeOH molecule.
Two of the remaining amide N–H groups, N(10)–H and N(22)–H, related by
Collect. Czech. Chem. Commun. 2009, Vol. 74, No. 6, pp. 901–925
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FIG. 2
ORTEP plot53 of the molecular structure of compound 31a (cis-isomer; arbitrary numbering of
atoms; 50% probability ellipsoids)
the pseudo two-fold axis within the peptide molecule, form intramolecular
hydrogen bonds with amide O atoms within the cyclic peptide molecule
and thereby form loops which can be described by a graph set motif55 of
S(10). N(4)–H and N(16)–H, also related by the pseudo-symmetry, form
intermolecular hydrogen bonds with other amide O atoms in two different
neighboring peptide molecules and thereby link the molecules into ex-
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TABLE III
Torsion angles of the backbone of compound 31a (atom numbering refers to Fig. 2)
Amino acid Atoms Torsion angles, °
Gly(1) φ1 C(24)–N(1)–C(2)–C(3) 79.5(9)
ψ1 N(1)–C(2)–C(3)–N(4) 179.7(6)
ω1 C(2)–C(3)–N(4)–C(5) 175.5(6)
Phe(2Me)(2) φ2 C(3)–N(4)–C(5)–C(6) 54.3(9)
ψ2 N(4)–C(5)–C(6)–N(7) 39.4(9)
ω2 C(5)–C(6)–N(7)–C(8) –177.0(7)
Aib(3) φ3 C(6)–N(7)–C(8)–C(9) 66.1(9)
ψ3 N(7)–C(8)–C(9)–N(10) 8(1)
ω3 C(8)–C(9)–N(10)–C(11) –179.3(7)
Gly(4) φ5 C(9)–N(10)–C(11)–C(12) –82.1(9)
ψ5 N(10)–C(11)–C(12)–N(13) 167.5(7)
ω5 C(11)–C(12)–N(13)–C(14) 172.7(7)
Gly(5) φ5 C(12)–N(13)–C(14)–C(15) –78.9(9)
ψ5 N(13)–C(14)–C(15)–N(16) –175.2(6)
ω5 C(14)–C(15)–N(16)–C(17) 173.9(7)
Phe(2Me)(6) φ6 C(15)–N(16)–C(17)–C(18) 55.1(9)
ψ6 N(16)–C(17)–C(18)–N(19) 37.3(9)
ω6 C(17)–C(18)–N(19)–C(20) 176.2(6)
Aib(7) φ7 C(18)–N(19)–C(20)–C(21) 55(1)
ψ7 N(19)–C(20)–C(21)–N(22) 31(1)
ω7 C(20)–C(21)–N(22)–C(23) –173.6(7)
Gly(8) φ8 C(21)–N(22)–C(23)–C(24) –79.6(9)
ψ8 N(22)–C(23)–C(24)–N(1) –15(1)
ω8 C(23)–C(24)–N(1)–C(2) –167.3(6)
tended chains. These chains run parallel to the [001] direction and both
interactions can be described by a graph set motif of C(8). The MeOH mole-
cules form intermolecular hydrogen bonds with amide O atoms in various
neighboring peptide molecules. Although there are a large number of inter-
actions, the total hydrogen bonding network serves only to link the mole-
cules into extended zig-zag chains which run parallel to the [001] direction.
CONCLUSIONS
The presented results show that peptides, containing 2,2-disubstituted
α-amino acids such as Phe(2Me) and Aib, can conveniently be prepared via
the ‘azirine/oxazolone method’, in which the sterically congested amino
acids are introduced by the coupling of an amino acid or peptide acid with
a 3-amino-2H-azirine. For cyclization experiments, we have chosen tetra-,
penta- and hexapeptides with two, three, and four 2,2-disubstitued α-amino
acids and Gly residues at the termini with the aim of avoiding steric hin-
drance in the ring-closing step. The cyclizations to the cyclopenta- and
cyclohexapeptide (15- and 18-membered ring, respectively) were achieved
in good yields by using DPPA in DMF, whereas in the cases of the tetra-
peptide a mixture of the monomeric cyclotetrapeptide and the dimer, i.e.,
a 24-membered cyclooctapeptide, in favor of the latter was obtained. Under
analogous reaction conditions, the tripeptide H-Gly-Phe(2Me)-Aib-OH gave
the dimeric, 18-membered cyclohexapeptide, as a mixture of two diastereo-
isomers exclusively.
The determination of the conformation of the linear pentapeptide
H-Gly-Phe(2Me)-Aib-Aib-Gly-OH by X-ray crystallography confirms the ex-
pected helical structure stabilized by two intramolecular hydrogen bonds
forming two consecutive β-turns. The crystal structure of the cyclopenta-
peptide also confirms the formation of a β-turn by an intramolecular
hydrogen bond but, surprisingly, Aib and Gly are included, not Phe(2Me)
and Aib. In the case of the dimeric cyclooctapeptide, two intramolecular
hydrogen bonds form two β-turns, both including Phe(2Me) and Aib.
The conformational properties of cyclopeptides containing 2,2-disub-
stituted α-amino acids will be investigated in solution. The presented syn-
thetic approach enables us to prepare such cyclopeptides of various ring
sizes conveniently.
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EXPERIMENTAL
Solvents were purified by standard procedures; tetrahydrofuran (THF) was distilled from
sodium/benzophenone, acetonitrile (MeCN) from P2O5, diethyl ether (Et2O) from sodium,
and dichloromethane (CH2Cl2) from anhydrous calcium chloride; dimethylformamide
(DMF, puriss.) was dried over molecular sieves. All other chemicals were of analytical grade
and were used without purification. The 3-amino-2H-azirines 2a, 2b, and 2c were prepared
according to the references cited in ref.33 Melting points (m.p.) were determined on
a Mettler-FP-5 apparatus; uncorrected. IR absorption spectra were measured on a Perkin–
Elmer-297 or 781 spectrophotometer; in KBr; absorptions in cm–1. 1H NMR spectra were re-
corded on a Varian XL-200, Bruker AC-300, Bruker AM-360 or Bruker AM-400 spectrometer.
13C NMR spectra were recorded on a Varian XL-200 spectrometer at 50.4 MHz; indicated
multiplicities of signals were determined by DEPT spectra. Solvents are indicated, TMS was
used as an internal standard (δ in ppm, coupling constants J in Hz). Mass spectra were mea-
sured on a Varian MAT-711, Finnigan MAT-90 or Finnigan SSQ-700 instrument; EI spectra at
70 eV, CI-MS with 2-methylpropane or NH3. Thin layer chromatography (TLC) on silica gel
60 F254 (Merck); column chromatography (CC, flash chromatography
65) with silica gel
Merck 60 (0.040–0.063 mm). High performance liquid chromatography (HPLC) with a
Varian 2510 instrument and Varian 2550 UV detector (254 nm) or Waters 600 E instrument
with Waters 484 UV detector (254 nm); Lichrosorb RP 18 or LichroCast RP 18 (reversed
phase) columns. Elemental analyses were performed in our Institute.
Abbreviations: AcOEt, ethyl acetate; Aib, 2-aminoisobutyric acid; Bn, benzyl; BOP, (1H-
benzo[d][1,2,3]triazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; CC,
column chromatography; DCC, N,N′-dicyclohexylcarbodiimide; DMAP, 4-(dimethylamino)-
pyridine; DMF, N,N-dimethylformamid; DMSO, dimethyl sulfoxide; DPPA, diphenyl phos-
phorazidate; Et2O, diethyl ether; Fmoc, (9H-fluoren-9-yl)methyloxycarbonyl; HPLC, high
performance liquid chromatography; MeCN, acetonitrile, MeOH, methanol, Phe(2Me),
2-methylphenylalanine, THF, tetrahydrofuran; TLC, thin layer chromatography; Tos, toluol-
sulfonyl (tosyl); Z, (benzyloxy)carbonyl.
Synthesis of Linear Peptides Containing α,α-Disubstituted α-Amino Acids
Z-Gly-Phe(2Me)-NMe2 (12). To a solution of Z-Gly-OH (1.0 g, 4.78 mmol) in THF (10 ml)
at 0 °C was added dropwise 2-benzyl-3-(dimethylamino)-2-methyl-2H-azirine (2a; 945 mg,
5.02 mmol). Then, the mixture was stirred at 0 °C for 15 min and at r.t. for 2 h. The white
precipitate was filtered off and washed with Et2O: 1.83 g (97%) of 12; colorless crystals;
m.p. 155.4 °C. IR (KBr): 3280m, 1730s, 1660s, 1615s, 1545m, 1535m, 1250s, 710m. 1H NMR
(200 MHz, CDCl3): 7.45–6.90 (3m, 10 arom. H, NH); 5.35 (br s, NH); 5.11 (s, PhCH2O); 3.79
(d, J = 5.5, CH2(Gly)); 3.57, 3.26 (AB, J = 14, PhCH2); 3.08 (br s, Me2N); 1.68 (s, MeC(2)).
13C
NMR (50.4 MHz, CDCl3): 171.6, 167.4 (2s, 2 CO(amide)); 156.4 (s, CO(urethane)); 136.4,
136.1 (2s, 2 arom. C); 130.0, 128.5, 128.2, 128.1, 128.0, 126.8 (6d, 10 arom. CH); 67.0 (t,
PhCH2O); 60.3 (s, C(2)(Phe(2Me))); 44.8 (t, CH2(Gly)); 40.9 (t, PhCH2); 38.3 (q, Me2N); 22.7
(q, MeC(2)). CI-MS: 398 (100, [M + 1]+). For C22H27N3O4 (397.48) calculated: 66.48% C,
6.58% H, 10.57% N; found: 66.64% C, 6.58% H, 10.71% N.
Z-Gly-Phe(2Me)-OH (13). A solution of 12 (1.70 g, 4.3 mmol) in THF/6 M HCl (1:1, 43 ml)
was stirred at 35 °C for 15 h. Then, 2 M HCl (43 ml) was added and the mixture extracted
with Et2O (3 ×). The organic phase was dried with Na2SO4 and the solvent evaporated. The
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oily residue was crystallized by addition of Et2O: 1.46 g (92%) of 13; colorless crystals; m.p.
130.0 °C. IR (KBr): 3350s, 1720s, 1635s, 1555m, 1530s, 1455m, 1280m, 1250s, 1225s, 1125s,
700m. 1H NMR (200 MHz, DMSO-d6): 12.61 (br s, COOH); 7.74 (br s, NH); 7.48 (t, J = 6,
NH(Gly)); 7.44–7.00 (3m, 10 arom. H); 5.06 (s, PhCH2O); 3.62 (d, J = 6, CH2(Gly)); 3.26,
3.05 (AB, J = 13.5, PhCH2); 1.26 (s, MeC(2)).
13C NMR (50.4 MHz, DMSO-d6): 174.8 (s,
COOH); 168.5 (s, CO(amide)); 156.5 (s, CO(urethane)); 137.1, 136.7 (2s, 2 arom. C); 130.4,
128.3, 127.8, 127.76, 127.7, 126.4 (6d, 10 arom. CH); 65.4 (t, PhCH2O); 58.6 (s,
C(2)(Phe(2Me))); 43.5 (t, CH2(Gly)); 40.0 (t, PhCH2); 22.5 (q, MeC(2)). CI-MS: 371 (79, [M +
1]+), 91 (100). For C20H22N2O5 (370.41) calculated: 64.85% C, 5.99% H, 7.56% N; found:
65.00% C, 5.93% H, 7.47% N.
Z-Gly-Phe(2Me)-Aib-N(Me)Ph (14). To a solution of 13 (1.39 g, 3.75 mmol) in THF (8 ml) at
0 °C was added dropwise 3-[(methyl)(phenyl)amino]-2,2-dimethyl-2H-azirine (2b; 687 mg,
3.94 mmol). Then, the mixture was stirred at 0 °C for 10 min and at r.t. for 15 h. The sol-
vent was evaporated, the oily residue crystallized from Et2O and dried under high vacuum:
1.71 g (84%) of 14; colorless crystals; m.p. 113.0 °C. IR (KBr): 3280m, 1725m, 1675s, 1650s,
1545m, 1495m, 1270m, 1240m, 710m, 700m. 1H NMR (400 MHz, CDCl3): 7.78 (br s, NH);
7.45–7.05 (3m, 15 arom. H); 6.65, 5.47 (2br s, 2 NH); 5.10 (s, PhCH2O); 3.80–3.75 (m,
CH2(Gly)); 3.37, 3.22 (AB, J = 13.5, PhCH2); 3.30 (s, MeN); 1.59 (s, MeC(2)); 1.43, 1.40 (2s,
Me2C).
13C NMR (50.4 MHz, CDCl3): 173.9, 171.2, 168.2 (3s, 3 CO(amide)); 156.5 (s,
CO(urethane)); 144.0, 136.2, 136.0 (3s, 3 arom. C); 130.2, 129.4, 128.5, 128.3, 128.2, 128.0,
126.9 (7d, 15 arom. CH); 67.1 (t, PhCH2O); 61.0, 58.9 (2s, C(2)(Phe(2Me)), C(2)(Aib)); 45.1
(t, CH2(Gly)); 41.8 (t, PhCH2); 41.6 (q, MeN); 24.6, 23.7 (2q, Me2C, MeC(2)). CI-MS: 545
(100, [M + 1]+). For C31H36N4O5 (544.66) calculated: 68.36% C, 6.66% H, 10.29% N; found:
68.22% C, 6.61% H, 9.96% N.
Z-Gly-Phe(2Me)-Aib-OH (15). 11.50 g (21.0 mmol) of 14 were dissolved in THF/6 M HCl
(1:1, 212 ml) at 50 °C and the solution stirred at r.t. for 6 h. The colorless precipitate was fil-
tered off and washed with cold Et2O, and the filtrate was extracted with Et2O (3 ×). The
combined organic phase was dried with Na2SO4 and the solvent evaporated. The crystalline
residue was dried under high vacuum: 9.26 g (96%) of 15; colorless crystals; m.p. 203.0 °C.
IR (KBr): 3360s, 3320m, 1725s, 1715s, 1660s, 1640s, 1560m, 1530m, 1255m, 1165m.
1H NMR (400 MHz, DMSO-d6): 7.66 (br s, 2 NH); 7.60 (t, J = 5.8, NH(Gly)); 7.40–7.05 (3m,
10 arom. H); 5.05 (s, PhCH2O); 3.59 (d, J = 5.7, CH2(Gly)); 3.32, 3.18 (AB, J = 13.5, PhCH2);
1.35, 1.32, 1.31 (3s, MeC(2), Me2C).
13C NMR (50.4 MHz, DMSO-d6): 175.5 (s, COOH);
172.3, 168.8 (2s, 2 CO(amide)); 156.6 (s, CO(urethane)); 137.0, 136.9 (2s, 2 arom. C); 130.4,
128.3, 127.7, 127.6, 126.2 (5d, 10 arom. CH); 65.4 (t, PhCH2O); 59.3, 55.2 (2s,
C(2)(Phe(2Me)), C(2)(Aib)); 44.2 (t, CH2(Gly)); 38.9 (t, PhCH2); 24.6 (q, Me2C); 23.3 (q,
MeC(2)). CI-MS: 456 (100, [M + 1]+). For C24H29N3O6 (455.52) calculated: 63.28% C, 6.42% H,
9.22% N; found: 63.47% C, 6.55% H, 9.09% N.
Z-Gly-Phe(2Me)-Aib-Aib-N(Me)Ph (16). To a solution of 15 (1.0 g, 2.20 mmol) in THF (20 ml)
and DMF (1 ml) at 0 °C was added dropwise 2b (402 mg, 2.31 mmol). Then, the mixture
was stirred at 0 °C for 10 min and at r.t. for 15 h. The solvent was evaporated and the oily
residue was dried under high vacuum: 1.27 g (92%) of 16; white foam. IR (KBr): 3300m (br),
2990m, 1670s (br), 1595m, 1530s, 1495m, 1455m, 1390m, 1380m, 1365m, 1270m, 1235m,
1095m, 745m, 705m. 1H NMR (400 MHz, CD3OD): 7.40–7.05 (m, 15 arom. H); 5.11, 5.04
(AB, J = 12.5, PhCH2O); 3.77, 3.66 (AB, J = 16.5, CH2(Gly)); 3.35 (s, MeN); 3.32, 2.98 (AB, J =
13.5, PhCH2); 1.51, 1.47, 1.43 (3s, 2 Me2C); 1.32 (s, MeC(2)).
13C NMR (50.4 MHz, CD3OD):
176.9, 176.1, 175.3, 172.8 (4s, 4 CO(amide)); 159.6 (s, CO(urethane)); 147.4, 138.3, 137.9
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(3s, 3 arom. C); 132.2, 130.6, 129.8, 129.5, 129.4, 129.1, 128.5, 128.3, 128.2 (9d, 15 arom.
CH); 68.1 (t, PhCH2O); 61.2 (s, C(2)(Phe(2Me))); 58.8, 58.5 (2s, 2 C(2)(Aib)); 45.7 (t,
CH2(Gly)); 41.7 (t, PhCH2); 41.3 (q, MeN); 27.0, 26.7, 26.5, 25.2, 23.8 (5q, 2 Me2C, MeC(2)).
CI-MS: 523 (100, [M + 1 – Ph(Me)N]+). For C35H43N5O6 (629.76) calculated: 66.75% C,
6.88% H, 11.12% N; found: 66.63% C, 7.12% H, 11.06% N.
Z-Gly-Phe(2Me)-Aib-Aib-OH (17). 11.44 g (18.2 mmol) of 16 were dissolved in THF/6 M HCl
(1:1, 182 ml) and the solution was stirred at r.t. for 6 h. The workup as for compound 15
gave 8.6 g (87%) of 17; colorless solid; m.p. 138.5 °C. IR (KBr): 3310m (br), 1730m (br),
1665s (br), 1530s (br), 1455m, 1280m, 1235m, 1160m. 1H NMR (400 MHz, acetone-d6):
10.52 (br s, COOH); 7.59, 7.53, 7.44 (3s, 3 NH); 7.40–7.10 (3m, 10 arom. H); 6.95 (X part of
ABX, J = 5.0, NH(Gly)); 5.13, 5.04 (AB, J = 12.5, PhCH2O); 3.81, 3.80 (AB of ABX, J = 16.5,
5.5, CH2(Gly)); 3.37, 3.05 (AB, J = 13.5, PhCH2); 1.48, 1.38 (2s, 2 Me2C); 1.30 (s, MeC(2)).
13C NMR (50.4 MHz, acetone-d6): 175.8, 174.9, 174.4, 171.7 (4s, COOH, 3 CO(amide));
158.3 (s, CO(urethane)); 137.9, 137.4 (2s, 2 arom. C); 131.6, 129.2, 128.9, 128.7, 128.6,
127.4 (6d, 10 arom. CH); 67.3 (t, PhCH2O); 60.5 (s, C(2)(Phe(2Me))); 57.4, 57.0 (2s,
2 C(2)(Aib)); 45.6 (t, CH2(Gly)); 40.8 (t, PhCH2); 26.3, 25.5, 25.4, 24.5, 23.4 (5q, 2 Me2C,
MeC(2)). CI-MS: 541 (42, [M + 1]+), 523 (100, [M + 1 – H2O]
+). For C28H36N4O7 (540.62) cal-
culated: 62.21% C, 6.71% H, 10.36% N; found: 62.20% C, 6.58% H, 10.19% N.
Z-Gly-Phe(2Me)-Aib-Aib-Aib-NMe2 (18). To a solution of 17 (9.68 g, 17.9 mmol) in THF (40 ml)
and DMF (8 ml) at 0 °C was added dropwise 3-(dimethylamino)-2,2-dimethyl-2H-azirine (2c;
2.35 g, 20.9 mmol). Then, the mixture was stirred at 0 °C for 15 h. The workup as for com-
pound 14 gave 11.52 g (99%) of 18; colorless solid; m.p. 203–212 °C. IR (KBr): 3320m,
3280m, 1705m, 1685s, 1655s, 1625s, 1550m, 1525m, 1270m. 1H NMR (400 MHz, DMSO-d6):
8.23, 7.87, 7.44 (3s, 3 NH); 7.57 (t, J = 6.0, NH(Gly)); 7.40–7.00 (2m, 10 arom. H, NH); 5.06,
4.99 (AB, J = 12.6, PhCH2O); 3.80–3.50 (2m, CH2(Gly)); 3.31 (s, Me2N); 3.29, 2.96 (AB, J =
13.3, PhCH2); 1.34, 1.33, 1.32, 1.30, 1.28 (5s, 3 Me2C); 1.19 (s, MeC(2)).
13C NMR (50.4 MHz,
DMSO-d6): 176.6, 173.7, 173.3, 172.2, 170.6 (5s, 5 CO(amide)); 156.9 (s, CO(urethane));
137.1, 136.9 (2s, 2 arom. C); 131.0, 128.5, 128.04, 128.00, 127.7, 126.5 (6d, 10 arom. CH);
65.7 (t, PhCH2O); 58.9 (s, C(2)(Phe(2Me))); 56.4, 56.2, 55.7 (3s, 3 C(2)(Aib)); 43.8 (t,
CH2(Gly)); 39.1 (t, PhCH2); 37.4 (br q, Me2N); 26.8, 26.1, 25.7, 24.0, 23.6, 22.5 (6q, 3 Me2C,
MeC(2)). EI-MS: 608 (100, [M – 45]+), 523 (26), 518 (12), 474 (11), 438 (24), 185 (14), 134
(70), 93 (31), 91 (75). For C34H48N6O7 (652.80) calculated: 62.56% C, 7.41% H, 12.87% N;
found: 62.37% C, 7.21% H, 12.78% N.
Z-Gly-Phe(2Me)-Aib-Aib-Aib-OH (19). 1.68 g (2.35 mmol) of 18 were dissolved in THF/6 M HCl
(1:1, 182 ml) and the solution was stirred at r.t. for 6 h. After this time, the reaction was not
complete. The workup as for compound 15 gave 0.92 mg (63%) of 19. The analogous hydro-
lysis of 200 mg (0.31 mmol) of 18 under reflux (16 h) gave 168 mg (88%) of 19; colorless
solid; m.p. 223–225 °C. IR (KBr): 3350m, 3310m, 1725m, 1680m, 1670m, 1650s, 1565m,
1555m, 1455w, 1280w, 1255w, 1150w. 1H NMR (400 MHz, DMSO-d6): 11.13 (br s, COOH);
7.60–7.45 (m, NH); 7.42, 7.38 (2s, 2 NH); 7.30–7.00 (m, 10 arom. H); 5.02, 4.91 (AB, J =
12.3, PhCH2O); 3.75–3.50 (m, CH2(Gly)); 3.26, 2.90 (AB, J = 13.0, PhCH2); 1.43, 1.37, 1.36,
1.31 (4s, 3 Me2C); 1.23 (s, MeC(2)).
13C NMR (50.4 MHz, DMSO-d6): 178.0 (s, COOH); 176.6,
176.3, 176.0, 172.4 (4s, 4 CO(amide)); 159.3 (s, CO(urethane)); 138.4, 138.0 (2s, 2 arom. C);
132.2, 129.9, 129.5, 129.4, 129.1, 128.1 (6d, 10 arom. CH); 67.9 (t, PhCH2O); 60.8 (s,
C(2)(Phe(2Me))); 58.1, 58.0, 57.1 (3s, 3 C(2)(Aib)); 45.6 (t, PhCH2); 41.3 (t, CH2(Gly)); 27.1,
26.8, 26.2, 25.3, 25.1, 24.8, 23.9 (7q, 3 Me2C, MeC(2)). A doubling of the signals at 176.6,
176.3, and 58.0 was observed, which disappeared at 60 °C. CI-MS: 626 (25, [M + 1]+), 608
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(100, [M + 1 – H2O]
+). For C32H43N5O8 (625.73) calculated: 61.43% C, 6.93% H, 11.19% N;
found: 61.13% C, 7.14% H, 11.04% N.
Z-Gly-Phe(2Me)-Aib-Aib-Gly-OMe (20). To a solution of 17 (7.0 g, 12.9 mmol) in DMF
(26 ml) at 0 °C was added DCC (2.67 g, 1.29 mmol). After 3 min, ZnCl2 (3.52 g, 25.8 mmol),
H-Gly-OMe·HCl (1.86 g, 14.8 mmol), and Et3N (1.50 g, 14.8 mmol) in DMF (10 ml) were
added and the mixture stirred at 0 °C to r.t. for 15 h. Filtration and evaporation of the sol-
vent gave a colorless oil, which was dissolved in CH2Cl2, washed with 1 M NaOH, 2 M HCl,
and saturated NaCl solution (2 × each). The organic phase was dried over Na2SO4, the sol-
vent evaporated, and the residue purified by CC (MeOH/CH2Cl2 5:95): 7.21 g (91%) of 20;
colorless foam. IR (KBr): 3320m (br), 1755m, 1710m, 1665s (br), 1545s, 1530s, 1455m,
1385m, 1275m (br), 1230m, 1195m, 1180m. 1H NMR (400 MHz, CDCl3): 7.72 (br s, NH);
7.45–7.05 (2m, 10 arom. H, NH); 6.93, 6.68, 6.08 (3br s, 3 NH); 5.09, 4.96 (AB, J = 12.5,
PhCH2O); 4.02 (d, J = 5.0, CH2(Gly)); 3.80–3.65 (m, CH2(Gly-OMe)); 3.62 (s, MeO); 3.22,
2.99 (AB, J = 13.7, PhCH2); 1.54, 1.45 (2s, 2 Me2C); 1.38 (s, MeC(2)).
13C NMR (50.4 MHz,
CHCl3): 176.1 (s, CO(ester)); 173.9, 173.6, 170.6, 170.2 (4s, 4 CO(amide)); 157.5 (s, CO(ure-
thane)); 136.0, 135.3 (2s, 2 arom. C); 130.5, 128.6, 128.4, 128.3, 127.9, 127.2 (6d, 10 arom.
CH); 67.3 (t, PhCH2O); 59.8 (s, C(2)(Phe(2Me))); 57.2, 57.1 (2s, 2 C(2)(Aib)); 51.8 (q, MeO);
46.0 (t, PhCH2); 42.3, 41.3 (2t, 2 CH2(Gly)); 25.6, 25.4, 25.2, 25.0 (4q, 2 Me2C); 23.0 (q,
MeC(2)). CI-MS: 612 (4, [M + 1]+), 91 (100). For C31H41N5O8 (611.70) calculated: 60.87% C,
6.76% H, 11.45% N; found: 60.93% C, 6.93% H, 11.20% N.
Z-Gly-Phe(2Me)-Aib-Aib-Gly-OH. To a solution of 20 (2.0 g, 3.27 mmol) in MeOH (25 ml)
at r.t., 2 M NaOH (11 ml) was slowly added. The reaction was complete after 25 min (TLC),
2 M HCl was added until pH 1 was reached, and the mixture was extracted with Et2O (3 ×)
and CH2Cl2 (2 ×). The combined organic phase was dried over Na2SO4, filtered, and the
solvent evaporated. The oily residue was dried under high vacuum: 1.60 g (82%) of
Z-Gly-Phe(2Me)-Aib-Aib-Gly-OH; colorless foam. IR (KBr): 3310s, 3270s, 1705m, 1680s,
1670s, 1645m, 1625m, 1540s, 1385m, 1265m, 1230w, 1195w, 1165w. 1H NMR (400 MHz,
CD3OD): 7.70 (s, NH); 7.40–7.0 (m, 10 arom. H); 5.11, 5.06 (AB, J = 12.5, PhCH2O); 4.00,
3.84 (AB, J = 17.7, CH2(Gly)); 3.84, 3.67 (AB, J = 16.7, CH2(Gly)); 3.37, 3.01 (AB, J = 13.6,
PhCH2); 1.50, 1.49, 1.39, 1.38 (4s, 2 Me2C); 1.33 (s, MeC(2)).
13C NMR (50.4 MHz, CD3OD):
178.1 (s, COOH); 176.7, 176.4, 173.1, 172.4 (4s, 4 CO(amide)); 159.5 (s, CO(urethane));
138.1, 137.6 (2s, 2 arom. C); 132.0, 129.7, 129.4, 129.3, 128.9, 128.1 (6d, 10 arom. CH);
68.1 (t, PhCH2O); 60.9 (s, C(2)(Phe(2Me))); 58.3 (s, 2 C(2)(Aib)); 45.6 (t, PhCH2); 42.2, 41.5
(2t, 2 CH2(Gly)); 26.7, 26.4, 25.3, 24.9 (4q, 2 Me2C); 23.7 (q, MeC(2)). CI-MS: 580 (100,
[M + 1 – H2O]
+). For C30H39N5O8 (597.67) calculated: 60.29% C, 6.58% H, 11.72% N; found:
60.15% C, 6.85% H, 11.63% N.
H-Gly-Phe(2Me)-Aib-Aib-Gly-OH (21). To a solution of Z-Gly-Phe(2Me)-Aib-Aib-Gly-OH
(447 mg, 0.75 mmol) in MeOH (2 ml) and AcOEt (1 ml) was added 66 mg Pd/C (10%).
Then, H2 was bubbled through the stirred mixture at 40 °C for 9 h. Filtration and evapora-
tion of the solvent gave a oily residue, which was dried under high vacuum: 334 mg (96%)
of 21; colorless foam. IR (KBr): 3380m, 3270m, 1685s, 1660s, 1590s, 1540s, 1390w, 1285w,
1230w, 1195w. 1H NMR (360 MHz, DMSO-d6): 8.36 (br s, NH); 7.85, 7.46 (2s, 2 NH);
7.30–7.20, 7.10–7.05 (2m, 5 arom. H); 7.17 (X of ABX, J = 6.0, NH(Gly)); 3.52, 3.36 (AB of
ABX, J = 18.0, 6.0, CH2(Gly)); 3.37, 3.31 (AB, J = 14.5, CH2(Gly)); 3.27, 3.02 (AB, J = 13.4,
PhCH2); 1.38, 1.37 (2s, 2 Me2C); 1.20 (s, MeC(2)).
13C NMR (50.4 MHz, D2O): 177.4, 176.9,
176.8, 175.2 (4s, 4 CO(amide)); 166.9 (s, COOH); 138.5 (s, 1 arom. C); 131.1, 128.8, 127.7
(3d, 5 arom. CH); 60.6 (s, C(2)(Phe(2Me))); 57.5, 57.2 (2s, 2 C(2)(Aib)); 43.9 (t, PhCH2); 40.9,
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40.8 (2t, 2 CH2(Gly)); 24.9, 24.7, 24.6, 24.0 (4q, 2 Me2C); 22.4 (q, MeC(2)). FAB-MS: 464
(83, [M + 1]+), 304 (100).
Suitable crystals for X-ray crystal-structure determination were obtained from a solution
of 21 in MeOH/H2O by slow evaporation of the solvent.
Z-Gly-Phe(2Me)-Aib-Aib-Aib-Gly-OBn (23). To a stirred solution of 19 (677 mg, 1.08 mmol)
in DMF (2 ml) at 0 °C was added DCC (223 mg, 1.08 mmol). After 3 min, a solution of
H-Gly-OBn·TsOH (420 mg, 1.24 mmol) and Et3N (114 mg, 1.13 mmol) in DMF (1 ml) was
added, then ZnCl2 (301 mg, 2.21 mmol), and the mixture was stirred at 0 °C to r.t. for
2 days. Filtration and evaporation of the solvent gave a colorless oil, which was dissolved
in CH2Cl2 and washed with 1 M NaOH and 2 M HCl (2 ×). The organic phase was dried
over Na2SO4 and filtered, the solvent evaporated, and the residue crystallized by addition of
Et2O: 690 mg (83%) of 23; colorless crystals; m.p. 194.5–199.5 °C. IR (KBr): 3310s (br),
1710m, 1660s (br), 1550s, 1540s, 1530s, 1455m, 1385m, 1265m (br), 1235m (br), 1185m,
1170m. 1H NMR (400 MHz, DMSO-d6): 8.21, 7.90 (2s, 2 NH); 7.74 (X of ABX, J = 6.0,
NH(Gly)); 7.64 (s, NH); 7.57 (X of ABX, J = 5.8, NH(Gly)); 7.40–7.00 (2m, 15 arom. H, NH);
5.08 (s, PhCH2O); 5.09, 5.00 (AB, J = 12.6, PhCH2O); 3.94, 3.62 (AB of ABX, J = 17.0, 6.0,
CH2(Gly)); 3.93, 3.84 (AB of ABX, J = 17.3, 5.8, CH2(Gly)); 3.30, 2.94 (AB, J = 13.0, PhCH2);
1.37, 1.33, 1.291, 1.286 (4s, 3 Me2C); 1.19 (s, MeC(2)).
13C NMR (50.4 MHz, CD3OD, 49.8 °C):
178.1, 177.4, 176.9, 175.7, 172.4, 171.1 (6s, CO(ester), 5 CO(amide)); 158.6 (s, CO(ure-
thane)); 138.1, 137.5, 137.3 (3s, 3 arom. C); 131.9, 129.50, 129.46, 129.3, 129.2, 128.7,
127.9 (7d, 15 arom. CH); 68.0, 67.7 (2t, 2 PhCH2O); 60.8 (s, C(2)(Phe(2Me))); 58.3, 58.2,
58.0 (3s, 3 C(2)(Aib)); 45.6 (t, PhCH2); 42.4, 41.7 (2t, 2 CH2(Gly)); 26.6, 26.3, 26.1, 25.2,
24.8, 24.6 (6q, 3 Me2C); 23.5 (q, MeC(2)). FAB-MS: 795 (5, [M + Na]
+), 773 (10, [M + 1]+),
134 (100). For C41H52N6O9 (772.91) calculated: 63.72% C, 6.78% H, 10.87% N; found:
63.49% C, 6.68% H, 10.56% N.
H-Gly-Phe(2Me)-Aib-Aib-Aib-Gly-OH (24). To a solution of 23 (500 mg, 0.65 mmol) in
MeOH (2 ml) and DMF (1 ml) under argon was added 50 mg Pd/C (10%). Then, H2 was bub-
bled through the mixture at r.t. for 9 h. The precipitate was dissolved by addition of DMF,
then, the solution was filtered through Celite and the solvent evaporated. The residue was
crystallized from Et2O/MeOH: 271 mg (76%) of 24; colorless crystals; m.p. 211–213 °C.
1H NMR (400 MHz, DMSO-d6): 8.16, 7.63, 7.45 (3s, 3 NH); 7.40 (t, J = 5.5, NH(Gly));
7.35–7.05 (2m, 5 arom. H, NH); 3.63, 3.49 (AB of ABX, J = 17.1, 5.3, CH2(Gly)); 3.34, 3.26
(AB, J = 16.5, CH2(Gly)); 3.25, 2.99 (AB, J = 13.5, PhCH2); 1.37, 1.36, 1.33, 1.31, 1.29 (5s,
3 Me2C); 1.21 (s, MeC(2)). CI-MS: 531 (63, [M + 1 – H2O]
+), 353 (100). FAB-MS: 549 (17,
[M + 1]+), 474 (31, [M + 1 – Gly]+), 389 (41, [M + 1 – Gly – Aib]+), 304 (100, [M + 1 – Gly –
Aib – Aib]+), 191 (37, [M + 1 – Gly – Aib – Aib – Aib – CO]+).
H-Gly-Phe(2Me)-Aib-OH (26). As a minor product in the hydrogenolysis of Z-Gly-Phe(2Me)-
Aib-Gly-OBn (28), 80 mg of 26 were obtained from the HPLC purification (as for com-
pound 29). 1H NMR (400 MHz, DMSO-d6): 8.22, 8.20 (2s, 2 NH); 7.30–7.00 (2m, 5 arom. H);
3.60–3.35 (m, CH2(Gly)); 3.27, 3.18 (AB, J = 14.0, PhCH2); 1.33, 1.32 (2s, Me2C); 1.28 (s,
MeC(2)). FAB-MS: 322 (100, [M + 1]+).
Z-Gly-Phe(2Me)-Aib-Gly-OBn (28). To a stirred solution of 15 (280 mg, 0.62 mmol) in DMF
(1.3 ml) at 0 °C was added DCC (127 mg, 0.62 mmol). After 3 min, ZnCl2 (170 mg,
1.23 mmol) and a solution of H-Gly-OBn·TsOH (239 mg, 0.71 mmol) and Et3N (62 mg,
0.62 mmol) in DMF (1 ml) were added, and the mixture stirred at 0 °C to r.t. for 2 days. Fil-
tration through Celite and evaporation of the solvent at 70 °C gave a yellowish oil, which
was dissolved in CH2Cl2 and washed with 1 M NaOH and 1 M HCl, and saturated NaCl solu-
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tion (2 × each). The organic phase was dried over Na2SO4, filtered, and the solvent evapo-
rated: 350 mg (95%) of crude 28; colorless powder. 1H NMR (400 MHz, DMSO-d6): 8.03 (s,
NH); 7.76 (X of ABX, J = 5.8, NH(Gly)); 7.58 (X of ABX, J = 6.0, NH(Gly)); 7.43 (s, NH);
7.40–7.00 (m, 15 arom. H); 5.08 (s, PhCH2O); 5.05-4.95 (m, PhCH2O); 3.82, 3.78 (AB of
ABX, J = 17.5, 5.8, CH2(Gly)); 3.66, 3.40 (AB of ABX, J = 17.0, 6.0, CH2(Gly)); 3.24, 3.01 (AB,
J = 13.4, PhCH2); 1.35, 1.32 (2s, Me2C); 1.21 (s, MeC(2)).
H-Gly-Phe(2Me)-Aib-Gly-OH (29). To a suspension of 28 (1.98 g, 3.53 mmol) in MeOH
(7 ml) and AcOEt (30 ml) was added 200 mg Pd/C (10%). Then, H2 was bubbled through the
mixture at r.t. for 24 h. The mixture was filtered through Celite, the residue washed with
MeOH, and the filtrate evaporated. The yellowish, solid residue was dissolved in 1 M NaOH
and washed with Et2O (3 ×) and AcOEt (3 ×). The aqueous phase was neutralized with 2 M
HCl, washed with Et2O, and evaporated under high vacuum. The residue was dissolved in
H2O and passed through a XAD resin column. After the elution of NaCl with H2O, the
peptide with eluted with MeOH. The solvent was evaporated and the residue dried under
high vacuum: 1.09 g (85%) of crude 29. Purification by HPLC (Lichrosorb RP 18,
MeOH/H2O) gave 29 as a colorless solid.
1H NMR (400 MHz, DMSO-d6): 8.39 (br s, NH); 7.82
(s, NH); 7.35–7.05 (m, 5 arom. H, NH); 4.00–3.55 (br m, NH3
+); 3.55–3.30 (m, 2 CH2(Gly));
3.27, 3.00 (AB, J = 13.4, PhCH2); 1.38, 1.32, 1.23 (3s, MeC(2), Me2C). FAB-MS: 401 (14, [M +
Na]+), 379 (5, [M + 1]+), 134 (100).
Cyclization of Peptides Containing α,α-Disubstituted α-Amino Acids
Cyclo[Gly-Phe(2Me)-Aib-Aib-Gly] (22). In analogy to ref.57, argon was bubbled through a so-
lution of 21 (150 mg, 0.32 mmol) in DMF (30 ml) and the mixture cooled to 0 °C. A cooled
solution of DPPA (110 mg, 0.40 mmol) in DMF (9 ml) was added very slowly by means of
an infusion pump within 3.5 h. After the addition of NaHCO3 (138 mg, 1.64 mmol), the
mixture was stirred vigorously at 0 °C under argon for 6 days. Then, 2 M HCl was added un-
til pH 7 was reached, the mixture was diluted to 100 ml with distilled H2O, the salts removed
by treatment with XAD resin (analytical grade, type 2, 100–200 µm) and H2O (100 ml), and
the organic product was eluted with MeOH/H2O (1:1) and MeOH. The combined MeOH
phase was evaporated and the white residue (powder; 122 mg, 85%) purified by HPLC
(Lichrosorb RP 18, H2O/MeCN 95:1): 86 mg (60%) of 22.
1H NMR (400 MHz, DMSO-d6):
8.69, 8.63 (2s, 2 NH); 8.05–7.90 (m, 2 NH); 7.35–7.00 (2m, 5 arom. H, NH); 4.05–3.90 (m,
CH2(Gly)); 3.55–3.40 (m, CH2(Gly)); 3.34, 2.88 (AB, J = 13.5, PhCH2); 1.60, 1.45, 1.33, 1.30
(4s, 2 Me2C); 1.11 (s, MeC(2)).
13C NMR (50.4 MHz, CD3OD ): 178.4, 176.8, 174.5, 172.1,
171.2 (5s, 5 CO(amide)); 137.9 (s, 1 arom. C); 131.8, 129.1, 127.8 (3d, 5 arom. CH); 62.7 (s,
C(2)(Phe(2Me))); 58.8, 58.0 (2s, 2 C(2)(Aib)); 43.8, 43.5 (2t, 2 CH2(Gly)); 40.7 (t, PhCH2);
25.6, 25.0, 24.1, 23.4, 22.8 (5q, 2 Me2C, MeC(2)). FAB-MS: 446 (62, [M + 1]
+), 134 (100).
Suitable crystals for X-ray crystal-structure determination were obtained from a solution
of 22 in MeOH/H2O by slow evaporation of the solvent.
Cyclo[Gly-Phe(2Me)-Aib-Aib-Aib-Gly] (25). In analogy to compound 22, to a solution of 24
(70 mg, 0.13 mmol) in DMF (135 ml) at 0 °C, a solution of DPPA (42 mg, 0.15 mmol) in
DMF (10 ml) was added slowly. After the addition of NaHCO3 (54 mg, 0.64 mmol), the mix-
ture was stirred vigorously at 0 °C under argon for 4 days. Then, DMF was evaporated, the
residue was dissolved in MeCN/H2O (2:1) and purified by HPLC (Lichrosorb RP 18, H2O/
MeCN): 28 mg (42%) of 25. 1H NMR (300 MHz, CDCl3): 8.63 (s, NH); 7.55 (X of ABX, J =
7.1, 5.7, NH(Gly2)); 7.35–7.05 (2m, 5 arom. H); 7.19 (s, NH); 6.98 (X of ABX, J = 8.2, 3.5,
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NH(Gly1)); 6.83, 6.00 (2s, 2 NH); 4.59, 3.82 (AB of ABX, J = 17.0, 8.4, 3.6 CH2(Gly1)); 4.17,
3.43 (AB of ABX, J = 13.3, 7.7, 5.3 CH2(Gly2)); 3.34, 2.88 (AB, J = 13.4, PhCH2); 1.65, 1.62,
1.54, 1.52, 1.50, 1.42, 1.39 (7s, 3 Me2C, MeC(2)).
13C NMR (50.4 MHz, CDCl3): 175.7, 174.5,
174.1, 173.8, 173.5, 172.1 (6s, 6 CO(amide)); 134.1 (s, 1 arom. C); 130.7, 128.4, 127.4 (3d,
5 arom. CH); 60.5 (s, C(2)(Phe(2Me))); 57.5, 56.5 (2s, 3 C(2)(Aib)); 44.7, 44.2, 43.4 (3t,
2 CH2(Gly), PhCH2); 27.0, 26.6, 25.2, 24.9, 24.0, 23.9 (6q, 3 Me2C); 20.9 (q, MeC(2)).
FAB-MS: 553 (58, [M + Na]+), 531 (40, [M + 1]+).
Cyclo[Gly-Phe(2Me)-Aib-Gly-Phe(2Me)-Aib] (27). In analogy to the preparation of compound
22, to a suspension of 26 (40 mg, 0.13 mmol) in DMF (124 ml) at 0 °C, a solution of DPPA
(39 mg, 0.14 mmol) in DMF (9 ml) was added very slowly by means of an infusion pump
within 4 h. After the addition of NaHCO3 (52 mg, 0.62 mmol), the mixture was stirred vig-
orously at 0 °C under argon for 15 days. Then, DMF was evaporated under high vacuum (55
°C), the residue was dissolved in MeCN/H2O/MeOH and purified by HPLC (Lichrosorb RP
18, H2O/MeCN 95:1): 14 mg (37%) of 27. No cyclotripeptide could be detected.
1H NMR
(400 MHz, DMSO-d6, 23 °C): 8.23, 8.21, 7.63, 7.56 (4s, 4 NH); 7.52 (t, J = 5.3, NH(Gly1));
7.47 (X of ABX, J = 6.5, 4.1, NH(Gly2)); 7.30–7.00 (2m, 10 arom. H); 3.91, 3.69 (AB of ABX,
J = 17.1, 6.7, 4.0, CH2(Gly2)); 3.80 (d, J = 5.3, CH2(Gly1)); 3.21, 2.97 (AB, J = 13.3, PhCH2);
3.12, 3.03 (AB, J = 13.2, PhCH2); 1.42, 1.41, 1.35, 1.33 (4s, 2 Me2C); 1.20, 1.19 (2s,
2 MeC(2)). 1H NMR (400 MHz, DMSO-d6, 65 °C): 7.98, 7.97 (2s, 2 NH); 7.45 (t, J = 5.4,
NH(Gly1)); 7.40 (t, J = 5.7, NH(Gly2)); 7.35, 7.29 (2s, 2 NH); 7.30–7.05 (2m, 10 arom. H);
3.88, 3.72 (AB of ABX, J = 16.8, 6.3, 4.5, CH2(Gly2)); 3.80 (d, J = 5.4, CH2(Gly1)); 3.22, 3.04
(AB, J = 13.5, PhCH2); 3.18, 3.07 (AB, J = 13.5, PhCH2); 1.431, 1.425, 1.39, 1.38 (4s,
2 Me2C); 1.253, 1.247 (2s, 2 MeC(2)).
1H NMR (300 MHz, DMSO-d6, 123 °C): 7.78 (br s,
2 NH); 7.45–7.30 (m, 2 NH); 7.30–7.00 (2m, 10 arom. H, 2 NH); 3.95–3.65 (m, 2 CH2(Gly));
3.30–3.05 (m, 2 PhCH2); 1.44, 1.42 (2s, 2 Me2C); 1.30, 1.29 (2s, 2 MeC(2)).
13C NMR
(50.4 MHz, DMSO-d6): 174.2, 172.7, 172.4, 169.7, 169.6 (5s, 6 CO(amide)); 136.9, 136.6
(2s, 2 arom. C); 130.5, 127.8, 126.4, 126.3 (4d, 10 arom. CH); 59.4, 59.3, 57.0, 56.9 (4s,
2 C(2)(Phe(2Me)), 2 C(2)(Aib)); 41.8, 40.7, 40.1, 40.0 (4t, 2 CH2(Gly), 2 PhCH2); 26.3, 26.0,
24.8, 24.6 (4q, 2 Me2C); 22.1, 21.9 (2q, 2 MeC(2)). FAB-MS: 629 (41, [M + Na]
+), 607 (100,
[M + 1]+).
Cyclo[Gly-Phe(2Me)-Aib-Gly] (30) and cyclo[Gly-Phe(2Me)-Aib-Gly-Gly-Phe(2Me)-Aib-Gly] (31).
In analogy to the preparation of compound 22, to a solution of 29 (70 mg, 0.19 mmol) in
DMF (200 ml) at 0 °C, a solution of DPPA (67 mg, 0.24 mmol) in DMF (9 ml) was added
very slowly by means of an infusion pump within 3 h. After the addition of NaHCO3 (80
mg, 0.95 mmol), the mixture was stirred vigorously at 4 °C under argon for 5 days. Then,
DMF was evaporated, the residue was dissolved in H2O, the pH was adjusted to 7 by addi-
tion of 2 M HCl, the salts were removed with XAD resin and the organic material eluted
with H2O, MeOH/H2O (1:1) and MeOH. The solvents were evaporated and the residue puri-
fied by HPLC (Lichrosorb RP 18, H2O/MeCN 95:5 to MeCN 100): Fraction 1: 9 mg (13.5%)
of 30; fraction 2: 21 mg (31.5%) of 31 as a mixture of two diastereoisomers.
Data of 30: FAB-MS: 383 (100, [M + Na]+), 361 (55, [M + 1]+).
Data of 31: FAB-MS: 743 (50, [M + Na]+), 721 (100, [M + 1]+). The two diastereoisomers of
31 were separated by HPLC.
Data of 31a: 1H NMR (400 MHz, CDCl3): 8.25 (br s, NH(Gly1), NH(Gly5)); 7.91 (br s,
2 NH); 7.76 (t, J = 5.8, NH(Gly2), NH(Gly8)); 7.40–7.05 (2m, 10 arom. H); 6.20 (br s, 2 NH);
4.18, 3.56 (AB of ABX, J = 15.5, 6.0, 5.3, CH2(Gly2), CH2(Gly8)); 4.07, 3.77 (AB of ABX, J =
17.2, 7.0, 5.4, CH2(Gly1), CH2(Gly5)); 3.23, 2.99 (AB, J = 13.0, 2 PhCH2); 1.48, 1.46 (2s,
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2 Me2C); 1.37 (s, 2 MeC(2)).
13C NMR (50.4 MHz, CD3OD): 178.8, 176.5, 173.2, 171.8 (4s,
8 CO(amide)); 137.6 (s, 2 arom. C); 132.2, 129.5, 128.3 (3d, 10 arom. CH); 61.2, 58.7 (2s,
2 C(2)(Phe(2Me)), 2 C(2)(Aib)); 44.2, 43.9 (2t, 4 CH2(Gly)); 42.0 (t, 2 PhCH2); 26.1, 25.6 (2q,
2 Me2C); 23.1 (q, 2 MeC(2)). FAB-MS: 743 (62, [M + Na]
+), 721 (100, [M + 1]+).
Suitable crystals for X-ray crystal-structure determination were obtained from a solution
of 31a in MeOH by slow evaporation of the solvent.
Data of 31b: 1H NMR (400 MHz, CDCl3): 8.27 (br s, NH(Gly1), NH(Gly5)); 7.71 (t, J = 5.8,
NH(Gly2), NH(Gly8)); 7.40-7.10 (2m, 10 arom. H, 2 NH); 6.33 (br s, 2 NH); 3.98, 3.82 (AB of
ABX, J = 17.3, 6.2, 5.8, CH2(Gly1), CH2(Gly5)); 4.00–3.70 (2m, CH2(Gly2), CH2(Gly8)); 3.17,
3.12 (AB, J = 13.3, 2 PhCH2); 1.46, 1.44, 1.43 (3s, 2 Me2C, 2 MeC(2)).
13C NMR (50.4 MHz,
CD3OD): 177.7, 176.3, 172.9, 171.5 (4s, 8 CO(amide)); 137.5 (s, 2 arom. C); 132.0, 129.2,
127.9 (3d, 10 arom. CH); 60.8, 58.3 (2s, 2 C(2)(Phe(2Me)), 2 C(2)(Aib)); 43.8, 43.5 (2t,
4 CH2(Gly)); 41.4 (t, 2 PhCH2); 27.3 (q, 2 MeC(2)); 24.0, 22.3 (2q, 2 Me2C). FAB-MS: 721
(100, [M + 1]+). ESI-MS: 743 (100, [M + Na]+).
X-ray Crystal-Structure Determination of 21, 22, and 31a
The measurements for 21 and 22 were performed on a Nicolet R3 diffractometer, those for
31a on a Rigaku AFC5R diffractometer using graphite-monochromatized MoKα radiation
(λ = 0.71073 Å) and, in the case of 31a, a 12-kW rotating anode generator. The data collec-
tion and refinement parameters are given in Table IV, and views of the molecules are shown
in Figs. 1 and 2. The intensities were corrected for Lorentz and polarization effects, but not
for absorption. Equivalent reflections were merged. The structures were solved by direct
methods using SHELXS86 66, which revealed the positions of all non-H atoms. In the case of
21, the asymmetric unit contains one molecule of the peptide plus four molecules of water.
The peptide molecule is protonated at the terminal amino group. Presumably the molecule
is a zwitterion with the terminal hydroxy group instead of carboxylate function; an H atom
could not be located here, but this terminal group shows disorder of the O atoms, which
might inhibit the detection of the hydroxy H atom, even if present. Two sets of overlapping
positions were defined for the O atoms of the terminal carboxylate group and the site occu-
pation factor of the major conformation refined to 0.529(13). Similarity restraints were ap-
plied to the chemically equivalent bond lengths and angles involving the disordered
O atoms and one O–H bond length for one of the water molecules [O(7)] was also re-
strained. In the case of 22, the asymmetric unit contains one peptide molecule plus one
molecule of water; in the case of 31a, the asymmetric unit contains one peptide molecule
plus five molecules of MeOH, one of which is disordered. Two positions were defined for the
atoms of the disordered MeOH molecule and the site occupation factor of the major orienta-
tion refined to 0.760(8). The C–O bond lengths of the two orientations were restrained to
1.45(1) Å, while these atoms were restrained to have similar atomic displacement parame-
ters. Atom C(6) was also restrained to have pseudo-isotropic atomic displacement
parameters. The non-H atoms in each structure were refined anisotropically. For 21, the
amide and most water H atoms were placed in the positions indicated by a difference elec-
tron density map and their positions were refined together with individual isotropic dis-
placement parameters. One H atom could not be located for each of the water molecules
O(7) and O(9), while none could be located for water molecule O(10). For 22, the amide and
water H atoms were placed in the positions indicated by a difference electron density map
and their positions were refined together with individual isotropic displacement parameters.
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TABLE IV
Crystallographic data of compounds 21, 22, and 31a
Parameter 21 22 31a
Crystallized from MeOH/H2O MeOH/H2O MeOH
Empirical formula C22H33N5O6·4H2O C22H31N5O5·H2O C36H48N8O8·5MeOH
Formula weight, g mol–1 535.59 463.53 881.03
Crystal color, habit colorless, prism colorless, prism colorless, prism
Temperature, K 294(1) 294(1) 173(1)
Crystal system monoclinic orthorhombic monoclinic
Space group P21/n Pna21 P21/c
Z 4 4 4
Reflections for cell
determination
25 25 22
2θ range for cell
determination, °
20–28 20–26 37–42
Unit cell parameters
a, Å 11.091(4) 21.972(3) 29.064(10)
b, Å 17.068(5) 9.498(1) 10.395(5)
c, Å 15.883(4) 11.684(1) 16.108(9)
β, ° 104.12(2) 90 96.76(6)
V, Å3 2915(1) 2438.3(5) 4832(4)
Dx, g cm
–3 1.220 1.263 1.211
µ(MoKα), mm–1 0.0961 0.0929 0.0904
Scan type ω ω ω
2θmax, ° 46 55 40
Total reflections measured 4885 3197 4585
Symmetry independent
reflections
4071 2939 4169
Reflections with I > 2σ(I) 3048 2188 2318
Reflections used in
refinement
4071 2939 4169
Parameters refined;
restraints
399; 7 332; 1 593; 38
Final R(F) (I > 2σ(I)
reflections)
0.0474 0.0435 0.0712
wR(F2) (all data) 0.1283 0.0905 0.2181
Weightsa: a; b 0.0647; 0.7960 0.0357; 0.1956 0.1235; 0
Goodness of fit 1.032 1.053 1.033
Secondary extinction
coefficient
0.0070(9) 0.0040(8) 0.005(1)
Final ∆max/σ 0.001 0.001 0.001
∆ρ (max; min), e Å–3 0.19; –0.14 0.16; –0.16 0.54; –0.58
a w = [σ2(Fo
2) + (aP)2 + bP]–1, where P = (Fo
2 + 2Fc
2)/3.
All remaining H atoms of 21 and 22 and all H atoms of 31a were placed in geometrically
calculated positions and refined by using a riding model where each H atom was assigned a
fixed isotropic displacement parameter with a value equal to 1.2Ueq of its parent C atom
(1.5Ueq for the methyl groups). The refinement of each structure was carried out on F
2 by
using full-matrix least-squares procedures, which minimised the function Σw(Fo
2 – Fc
2)2. A
correction for secondary extinction was applied in all cases. Neutral atom scattering factors
for non-H atoms were taken from ref.67a, and the scattering factors for H atoms from ref.68.
Anomalous dispersion effects were included in Fc
69; the values for f ′ and f ′′ were those of
ref.67b. The values of the mass attenuation coefficients are those of ref.67c. All calculations
were performed using the SHELXL97 70 program.
CCDC 720132–720134 contain the supplementary crystallographic data for this paper.
These data can be obtained free of charge from the Cambridge Crystallographic Data Centre
via http://www.ccdc.cam.ac.uk/data_request/cif.
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